DNA Vaccines Market Set for Explosive Growth at 42.03% CAGR Through 2031, Led by North America's Nearly 45% Market Share | DataM Intelligence

The Global DNA Vaccines Market is projected to grow at an exceptional CAGR of 42.03% during the forecast period 2024-2031.
This rapid growth is driven by rising interest in next-generation vaccine platforms, increasing prevalence of infectious diseases, and strong R&D investments in genetic immunization technologies. Additionally, the advantages of DNA vaccines such as low production cost, faster development timelines, and robust immune response accelerating global market adoption.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/dna-vaccines-market?ram

United States: Key Industry Developments
✅ October 2025 ongoing clinical evaluations of IMUNON's PlaCCine® DNA vaccine platform for COVID-19 Omicron variant XBB.1.5 showed potent single-dose immunity in phase 1 trials.​

✅ September 2025: Zydus Cadila's ZyCoV-D DNA vaccine continued evaluations for optimized two-dose regimens in adults and children.​

✅ August 2025: Market valued at US$590 million with North America leading focus on thermostable DNA vaccine formulations to improve storage and access.​

Asia Pacific / Japan: Key Industry Developments
✅ October 2025: Takeda Pharmaceutical expanded research on DNA vaccines targeting infectious and chronic diseases.​

✅ September 2025: Collaboration between Japanese biotech firms and academic institutes accelerated DNA vaccine platform innovations.​

✅ August 2025: Government funding increased for DNA vaccine development against endemic viral infections; Asia-Pacific noted as fastest-growing region.​

Key Merges and Acquisitions(2025):
✅ BioNTech acquires CureVac (Indirect Impact): In June 2025, BioNTech announced an agreement to acquire CureVac in an all-stock deal valued at approximately $1.25 billion. This major M&A move by BioNTech, a leader in mRNA technology, is focused on bolstering its capabilities in developing mRNA-based cancer immunotherapies, reflecting a major push into the oncology vaccine space that also heavily involves DNA vaccine research.

✅ Maravai LifeSciences acquires Officinae Bio's DNA/RNA business (Indirect Impact): In February 2025, Maravai LifeSciences completed the acquisition of Officinae Bio's DNA and RNA business. This acquisition combines AI-driven mRNA design platforms with existing manufacturing capabilities, illustrating the industry-wide trend of integrating advanced technology to streamline the development and manufacturing of gene-based vaccines, including DNA vaccines.

✅ Merck opens $1 billion vaccine manufacturing plant (Indirect Impact): In March 2025, Merck opened a new state-of-the-art vaccine manufacturing plant in North Carolina. This significant investment in manufacturing infrastructure reflects the large-scale commitment by major pharmaceutical companies to increase global vaccine production capacity for various types of vaccines, including potential future commercial DNA vaccines.

Market Segmentation Analysis:
-By Type: Animal DNA Vaccines Lead
Animal DNA Vaccines hold the highest share at around 55% as of 2025, fueled by approved products like Oncept for canine melanoma and West Nile-Innovator for viral diseases in animals, plus strong aquaculture adoption for fish pathogens.​
Human DNA Vaccines claim the remaining 45%, growing faster due to ongoing research for infectious diseases and cancer, with candidates like ZyCov-D advancing clinical trials.​

-By Application: Veterinary Diseases Dominate
Veterinary Diseases capture over 60% market share, driven by widespread use of prophylactic vaccines against animal infections like hematopoietic necrosis virus and West Nile Virus.​
Human Diseases hold about 40%, with potential for rapid expansion from R&D targeting human pathogens amid rising antibiotic resistance.​

-By End User: Animal Health Prevails
Animal Health leads with approximately 52% share, supported by established vaccines in veterinary and aquaculture settings for disease prevention.​
Human Health accounts for 48%, boosted by hospital distribution and preventive focus, though research institutions grow quickest via clinical trials.​

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=dna-vaccines-market?ram (Purchase 2 or more Reports and get 50% Discount)

Growth Drivers:
-Rising prevalence of cancer and infectious diseases in humans and animals, driving demand for effective immunotherapies and treatments.​

-Increasing antibiotic-resistant pathogens, necessitating advanced vaccine solutions like DNA vaccines for long-lasting protection.​

-Advancements in genetic engineering, delivery systems (such as electroporation and nanocarriers), and DNA technology enabling rapid, targeted vaccine development.​

-Demand for rapid, scalable vaccines suitable for pandemics and outbreaks due to quick design, production, and room-temperature stability.​

-Growing research initiatives, investments in cancer immunotherapies, and high potential in emerging economies.​

Regional Insights:
-North America commands the largest share of the DNA Vaccines Market, estimated at nearly 45% as of recent assessments, driven by advanced healthcare infrastructure, extensive research initiatives, and a high concentration of biotech hubs in the United States. This dominance is bolstered by robust clinical trials, government funding, and established veterinary applications for companion animals. Leading players and collaborations between academic institutions and biotech firms further accelerate innovation and adoption in the region.​

-Europe holds a significant but secondary market share, supported by strong investments in personalized medicine, gene therapy research, and regulatory frameworks conducive to vaccine development. Growth here is fueled by increasing focus on immunotherapies for infectious diseases and cancer, positioning it as a key contributor behind North America. Ongoing R&D efforts in countries like Germany and the UK enhance its competitive standing.​

-Asia Pacific ranks third in market share, exhibiting the fastest growth rate due to rapid biotech expansion in countries such as India and China, alongside rising demand for innovative vaccines against pathogens. The region's accelerating CAGR reflects investments in manufacturing capabilities and addressing infectious disease burdens. Emerging infrastructure and clinical trials are projected to narrow the gap with leading regions over time.​

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/dna-vaccines-market?ram

Key Players:
Inovio Pharmaceuticals, Inc. | Merck & Co. | Mitsubishi Tanabe | Dendreon Corporation | Astellas Pharma | Dynavax Technologies | Sanofi | Tekmira Pharmaceuticals | GlaxoSmithKline Corp | Protein Sciences Corp

Key Highlights (Top 5 Key Players) for DNA Vaccines Market:
-Inovio Pharmaceuticals, Inc. leads DNA vaccine development with its proprietary CELLECTRA delivery platform advancing candidates like INO-3107 toward BLA submission in 2025, focusing on recurrent respiratory papillomatosis and next-generation DNA medicines.​

-Merck & Co., Inc. contributes through collaborations enhancing DNA vaccine immunogenicity and delivery, positioning it among top players in a market projected to grow from USD 5.4 billion in 2024.​

-ASTELLAS PHARMA drives innovation in DNA vaccine platforms via strategic partnerships, supporting prophylactic and therapeutic applications in a sector expanding at 9.5% CAGR through 2031.​

-Dynavax Technologies advances DNA-based technologies for infectious diseases and cancer, benefiting from rising investments in the global DNA vaccines space valued at USD 553.89 million in 2024.​

-Sanofi S.A. integrates DNA vaccines into its broader portfolio, including immunogenicity enhancements through pharma-tech collaborations in a market forecasted to reach USD 10.2 billion by 2031.​

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.